Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Avihingsanon A, Maek-A-Nantawat W, Gatechompol S, Sapsirisavat V, Thiansanguankul W, Sophonphan J, Thammajaruk N, Ubolyam S, Burger DM, Ruxrungtham K. Avihingsanon A, et al. Int J Infect Dis. 2017 Aug;61:89-96. doi: 10.1016/j.ijid.2017.06.009. Epub 2017 Jun 13. Int J Infect Dis. 2017. PMID: 28627427 Free article. Clinical Trial.
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
van der Lugt J, Autar RS, Ubolyam S, Garcia EF, Sankote J, Avihingsanon A, Chuenyam T, Cooper DA, Lange J, Phanuphak P, Wit F, Ruxrungtham K, Burger D; HIV-NAT 019 Study Team. van der Lugt J, et al. Among authors: avihingsanon a. J Antimicrob Chemother. 2008 May;61(5):1145-53. doi: 10.1093/jac/dkn050. Epub 2008 Feb 18. J Antimicrob Chemother. 2008. PMID: 18285316 Clinical Trial.
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227.
Ruxrungtham K, Pedro RJ, Latiff GH, Conradie F, Domingo P, Lupo S, Pumpradit W, Vingerhoets JH, Peeters M, Peeters I, Kakuda TN, De Smedt G, Woodfall B; TMC125-C227 study group. Ruxrungtham K, et al. HIV Med. 2008 Nov;9(10):883-96. doi: 10.1111/j.1468-1293.2008.00644.x. Epub 2008 Sep 14. HIV Med. 2008. PMID: 18795960 Free article. Clinical Trial.
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Lewin SR, Ribeiro RM, Avihingsanon A, Bowden S, Matthews G, Marks P, Locarnini SA, Ruxrungtham K, Perelson AS, Dore GJ. Lewin SR, et al. Among authors: avihingsanon a. Hepatology. 2009 Apr;49(4):1113-21. doi: 10.1002/hep.22754. Hepatology. 2009. PMID: 19115219 Free PMC article. Clinical Trial.
Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults.
Walmsley S, Avihingsanon A, Slim J, Ward DJ, Ruxrungtham K, Brunetta J, Bredeek UF, Jayaweera D, Guittari CJ, Larson P, Schutz M, Raffi F. Walmsley S, et al. Among authors: avihingsanon a. J Acquir Immune Defic Syndr. 2009 Apr 1;50(4):367-74. doi: 10.1097/QAI.0b013e318198a815. J Acquir Immune Defic Syndr. 2009. PMID: 19214123 Clinical Trial.
271 results